Amgen Tells 4th Circ. No Point In Keeping CareFirst Suit Alive
Amgen urged the Fourth Circuit to overrule a Virginia federal judge's refusal to dismiss CareFirst's lawsuit accusing it of unlawfully delaying biosimilar competition for Enbrel, arguing that the health insurer's alleged...To view the full article, register now.
Already a subscriber? Click here to view full article